About SCM Lifescience
SCM Lifescience is a company based in Incheon (South Korea) founded in 2014 by Sun U Song. SCM Lifescience has raised $4.8 million across 1 funding round from investors including Duopharma Biotech Berhad. The company has 56 employees as of December 31, 2024. SCM Lifescience has completed 1 acquisition, including Argos Therapeutics. SCM Lifescience offers products and services including Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics. SCM Lifescience operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Incheon, South Korea
- Employees 56 as on 31 Dec, 2024
- Founders Sun U Song
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Scm Life Science
-
Annual Revenue
$559.21 K (USD)18.56as on Dec 31, 2024
-
Net Profit
-$8.39 M (USD)48.35as on Dec 31, 2024
-
EBITDA
-$7.09 M (USD)14.06as on Dec 31, 2024
-
Total Equity Funding
$4.8 M (USD)
in 1 rounds
-
Latest Funding Round
$4.8 M (USD), Series A
Oct 26, 2018
- Investors
-
Employee Count
56
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of SCM Lifescience
SCM Lifescience is a publicly listed company on the KRX with ticker symbol 298060 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of SCM Lifescience
SCM Lifescience offers a comprehensive portfolio of products and services, including Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics.
High-purity stem cells for treating incurable diseases.
Advanced immune cell treatments for disease management.
Cell-based solutions for tissue repair and regeneration.
Stem cell-derived skincare for consumer use.
Funding Insights of SCM Lifescience
SCM Lifescience has successfully raised a total of $4.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.8 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SCM Lifescience
SCM Lifescience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Duopharma Biotech Berhad.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for SCM Lifescience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SCM Lifescience
SCM Lifescience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Argos Therapeutics.
Investment portfolio details for SCM Lifescience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
An online gambling platform is operated for Tai Xiu games.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for SCM Lifescience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SCM Lifescience
Detailed financials for SCM Lifescience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scm Lifescience Comparisons
Peer comparison for SCM Lifescience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SCM Lifescience
SCM Lifescience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of SCM Lifescience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scm Lifescience
Complete news archive for SCM Lifescience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SCM Lifescience
SCM Lifescience was founded in 2014 and raised its 1st funding round 4 years after it was founded.
SCM Lifescience is headquartered in Incheon, South Korea.
Byong Kwan Son is the current CEO of SCM Lifescience.
SCM Lifescience is a funded company, having raised a total of $4.8M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at SCM Lifescience is 56.
Annual revenue of SCM Lifescience is $559.21K as on Dec 31, 2024.
SCM Lifescience develops stem cell therapeutics and related services. The company uses a proprietary subfractionation culturing method (SCM) to isolate mesenchymal stem cells (MSCs) from adipose tissue, bone marrow and periodontal ligaments. The procedure produces MSCs that are non-immunogenic in nature, and thus can be used as universal donor cells. SCM is investigating MSC therapeutics for indications like immune-related or inflammatory diseases such as graft-versus host disease, atopic dermatitis and pancreatitis. In addition, the company also offers CMO services for stem cell production and clonal stem cell banking services.
SCM Lifescience's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
SCM Lifescience offers Stem Cell Therapy, Immune Cell Therapy, Tissue Engineering Therapy, and Enseria Cosmetics.
Yes, SCM Lifescience is publicly traded on KRX under the ticker symbol 298060.
SCM Lifescience has made 1 acquisition, including Argos Therapeutics.
SCM Lifescience has 1 investor. Key investors include Duopharma Biotech Berhad.
The ticker symbol of SCM Lifescience is 298060 on KRX.